Caterina Chiappetta et al., Evaluation of the management of Hr-HPV+/PapTest- women: Results at 1-year recall. International Journal of Clinical and Experimental Pathology

Caterina Chiappetta1, Chiara Puggioni1, Eugenio Lendaro1, Jessica Cacciotti1, Roberto Zaralli1, Giovanna Migliore1, Paola Bellardini2, Vincenzo Petrozza1, Carlo Della Rocca1 Claudio Di Cristofano1

1UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Polo Pontino, I.C.O.T, Latina, Italy
2Screening Unit, Local Health Unit of Latina, Italy

Abstract:

With cervical cancer screening the choice of 1-year as a period of follow-up in positive high-risk HPV women without cytological lesions is still under discussion. We evaluated the management of these women and the role of HPV genotyping test. We did a cervical cancer screening study of women aged 35-64 with primary high-risk HPV test. Women positive for high-risk HPV with negative cytology were followed-up after 1 year. In this study we selected women with high-risk HPV+/PapTest- resulted high-risk HPV+ at recall and performed the PapTest and HPV genotyping test. The detection rate of squamous high grade (CIN2+) relative to the total screened cohort was 2.1‰, and it was 0.2‰ at the 1-year recall. The colposcopy performed in women referred at the 1-year recall accounted for 48.8% of the total (baseline + 1-year recall), and 84.3% of these women had no cytological lesions. The most frequent hr-HPV genotype detected was HPV16 and 66.7% of co-infections were due to HPV16 and HPV18. 54.5% of women presented a persistent infection at 1-year recall with the same HPV subtype, 50% of persistent infections was due to HPV16 and 16.7% of these were determined to be CIN2+ histological lesions. Our data show that it may be useful to extend the period of follow-up for women hr-HPV+/PapTest- so as to reduce the number of unnecessary colposcopies due to the transitory infections and that the genotyping test could help to identify the persistent infections in which HPV16 is involved.

Read the complete publication at this link

Products
Request information

Please insert your email address below, we will contact you soon.


I consent to privacy



2017-08-08T12:34:57+00:00